

<p>Relevant Background and Expertise (2000 characters)</p>	<p>Constanza has a Bachelor of Pharmacy from Pontificia Universidad Catolica in Chile and a Master of Health Economics from the University of Queensland. She is employed by the Centre for Health Economics Research & Evaluation (CHERE), University of Technology Sydney (UTS) since November 2017. Constanza is an evaluator for the Pharmaceutical Benefits Advisory Committee (PBAC) where she has to develop Commentaries in a timely manner, participate in meetings with the Department of Health (DoH), attend the Economic Sub-Committee (ESC) meetings and provide a fluent communication within internal evaluators. She is also involved in a number of economic evaluations conducted alongside clinical trials and is an associate investigator of an NHMRC funded clinical trial for which she will be conducting the economic analysis. The latter includes the support in the development of protocols/grants that include a health economic analysis, MBS and PBS data analysis, development of CRFs for data collection and publication of results. In July 2019, Constanza was promoted to a Senior research fellow position and since then, she is leading the provision of health technology assessments for the Medical Services Advisory Committee (MSAC). Similar to PBAC, MSAC requires the development of commentaries in a timely manner and also the conduction of full HTA reports for which broader research techniques are required. In her role as a senior evaluator, she also supervises evaluators and has a role in the quality assurance of Commentaries. In this role, she is the main contact person at CHERE with the DoH and is responsible for ensuring available internal capacity for the conduct of the reports and quality assurance. Constanza also has teaching responsibilities in health economics and economic evaluations. As part of her research duties, she writes and publishes articles in peer-reviewed journals.</p> <p>Constanza has more than 10 years of work experience related to critical appraisal of the evidence of pharmaceuticals and 8 years of experience in health economics, mainly health technology assessment.</p>
--	--